Mirikizumab for Crohn's disease

被引：0
|
作者：
Baker, Holly
机构：
来源：
LANCET GASTROENTEROLOGY & HEPATOLOGY | 2022年 / 7卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：117 / 117
页数：1
相关论文
共 50 条
  • [1] Mirikizumab for Crohn's disease
    Feetham, Laura
    Brierley, Rob
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2019, 4 (08): : 583 - 583
  • [2] Mirikizumab: A promising breakthrough in Crohn's disease treatment
    Aslam, Muaaz
    Ali, Mohammad Haris
    Irfan, Hamza
    HEALTH SCIENCE REPORTS, 2024, 7 (08)
  • [3] Effect of Mirikizumab on Inflammatory Biomarkers in a Phase 2 Study of Patients With Crohn's Disease
    D'Haens, Geert
    Schreiber, Stefan
    Louis, Edouard
    Sands, Bruce E.
    Valderas, Elisa Gomez
    Miller, Debra
    Agada, Noah
    Naegeli, April N.
    Pollack, Paul
    Schmitz, Jochen
    Van der Woude, Janneke
    Kierkus, Jaroslaw
    Sandborn, William J.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S418 - S419
  • [4] Evaluation of Symptom Improvement During Induction in Patients With Crohn's Disease Treated With Mirikizumab
    Sandborn, William J.
    Sands, Bruce E.
    Hindryckx, Peter
    Fischer, Monika
    Isaacs, Kim
    Naegeli, April N.
    Miller, Debra
    Valderas, Elisa Gomez
    Agada, Noah
    Pollack, Paul
    D'Haens, Geert
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S354 - S355
  • [5] MIRIKIZUMAB REDUCES ABDOMINAL PAIN IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE
    Loftus, Edward
    Pollack, Paul
    Hunter, Theresa
    Shan, Mingyang
    Chan, Lai-Shan
    Deckard, Deanilee
    Cross, Raymond
    GASTROENTEROLOGY, 2022, 162 (03) : S15 - S15
  • [6] Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn's Disease
    Sands, Bruce E.
    Peyrin-Biroulet, Laurent
    Kierkus, Jaroslaw
    Higgins, Peter D. R.
    Fischer, Monika
    Jairath, Vipul
    Hirai, Fumihito
    D'Haens, Geert
    Belin, Ruth M.
    Miller, Debra
    Gomez-Valderas, Elisa
    Naegeli, April N.
    Tuttle, Jay L.
    Pollack, Paul F.
    Sandborn, William J.
    GASTROENTEROLOGY, 2022, 162 (02) : 495 - 508
  • [7] MIRIKIZUMAB REDUCES ABDOMINAL PAIN IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE
    Loftus, Edward
    Pollack, Paul
    Hunter, Theresa
    Shan, Mingyang
    Chan, Lai-Shan
    Deckard, Deanilee
    Cross, Raymond
    INFLAMMATORY BOWEL DISEASES, 2022, 28 : S15 - S15
  • [8] Effect of Mirikizumab on Inflammatory Biomarkers in a Phase 2 Study of Patients With Crohn's Disease
    D'Haens, Geert
    Schreiber, Stefan
    Louis, Edouard
    Sands, Bruce E.
    Valderas, Elisa Gomez
    Miller, Debra
    Agada, Noah
    Naegeli, April N.
    Pollack, Paul
    Schmitz, Jochen
    Van der Woude, Janneke
    Kierkus, Jaroslaw
    Sandborn, William J.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S366 - S366
  • [9] Effects of Mirikizumab on Histologic Resolution of Crohn's Disease in a Randomized Controlled Phase 2 Trial
    Magro, Fernando
    Protic, Marijana
    De Hertogh, Gert
    Chan, Lai Shan
    Pollack, Paul
    Jairath, Vipul
    Carlier, Hilde
    Hon, Emily
    Feagan, Brian G.
    Harpaz, Noam
    Pai, Rish
    Reinisch, Walter
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2024, 22 (09)
  • [10] MIRIKIZUMAB THERAPY IS ASSOCIATED WITH IMPROVED FATIGUE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE
    Reguiro, Miguel D.
    Fischer, Monika
    Rubin, David T.
    Shan, Mingyang
    Deckard, Deanilee
    Pollack, Paul
    Hunter, Theresa
    Chan, Lai Shan
    Hindryckx, Pieter
    GASTROENTEROLOGY, 2021, 160 (06) : S354 - S355
12345